Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
38.56 (1y: +27%)
Market Cap 4.36 B P/E(ttm)
Enterprise Value 7.09 B P/B 3.90
ENDP- NAS (USA)
Endo Health Solutions Inc
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$38.56
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash to Debt 0.173
ENDP's Cash to Debt is ranked lower than
58% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. ENDP: 0.173 )
ENDP' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 0.17
Equity to Asset 0.163
ENDP's Equity to Asset is ranked lower than
58% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ENDP: 0.163 )
ENDP' s 10-Year Equity to Asset Range
Min: 0.16   Max: 0.76
Current: 0.16
0.16
0.76
F-Score: 3
Z-Score: 0.83
M-Score: -3.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) -18.20
ENDP's Operating margin (%) is ranked lower than
61% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.80 vs. ENDP: -18.20 )
ENDP' s 10-Year Operating margin (%) Range
Min: -18.2   Max: 38.2
Current: -18.2
-18.2
38.2
Net-margin (%) -24.5
ENDP's Net-margin (%) is ranked lower than
62% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. ENDP: -24.5 )
ENDP' s 10-Year Net-margin (%) Range
Min: -79.4   Max: 24.7
Current: -24.5
-79.4
24.7
ROE (%) -69
ENDP's ROE (%) is ranked lower than
67% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. ENDP: -69 )
ENDP' s 10-Year ROE (%) Range
Min: -79.1   Max: 24
Current: -69
-79.1
24
ROA (%) -11.3
ENDP's ROA (%) is ranked lower than
62% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. ENDP: -11.3 )
ENDP' s 10-Year ROA (%) Range
Min: -33.5   Max: 15.1
Current: -11.3
-33.5
15.1
ROC (Joel Greenblatt) (%) -259.10
ENDP's ROC (Joel Greenblatt) (%) is ranked lower than
68% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.40 vs. ENDP: -259.10 )
ENDP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -259.1   Max: 1497.6
Current: -259.1
-259.1
1497.6
Revenue Growth (%) 20.4
ENDP's Revenue Growth (%) is ranked higher than
94% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ENDP: 20.4 )
ENDP' s 10-Year Revenue Growth (%) Range
Min: 10.8   Max: 21.9
Current: 20.4
10.8
21.9
ยป ENDP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ENDP Guru Trades in Q2 2012

Tom Russo 100 sh (New)
Paul Tudor Jones 108,800 sh (New)
Louis Moore Bacon 75,000 sh (New)
Steven Cohen 4,743,631 sh (+98.93%)
Joel Greenblatt 26,053 sh (+53.03%)
Lee Ainslie 6,437,482 sh (+16.86%)
Scott Black 249,122 sh (+15.73%)
Jim Simons 601,193 sh (+15.37%)
John Hussman 1,914,000 sh (unchged)
David Dreman 92,625 sh (unchged)
Jeremy Grantham 90,900 sh (-11.06%)
Chuck Royce 649,852 sh (-37.55%)
» More
Q3 2012

ENDP Guru Trades in Q3 2012

Ray Dalio 30,243 sh (New)
Joel Greenblatt 240,394 sh (+822.71%)
Louis Moore Bacon 100,000 sh (+33.33%)
David Dreman 92,775 sh (+0.16%)
Paul Tudor Jones Sold Out
Tom Russo Sold Out
Scott Black 246,031 sh (-1.24%)
Steven Cohen 4,625,076 sh (-2.5%)
Lee Ainslie 5,088,143 sh (-20.96%)
Jeremy Grantham 65,197 sh (-28.28%)
John Hussman 1,204,000 sh (-37.1%)
Jim Simons 257,093 sh (-57.24%)
Chuck Royce 246,000 sh (-62.15%)
» More
Q4 2012

ENDP Guru Trades in Q4 2012

Paul Tudor Jones 10,800 sh (New)
Joel Greenblatt 358,103 sh (+48.97%)
Jim Simons 378,293 sh (+47.14%)
David Dreman 93,914 sh (+1.23%)
Chuck Royce 246,000 sh (unchged)
Jeremy Grantham 37,000 sh (unchged)
Lee Ainslie Sold Out
Ray Dalio Sold Out
Scott Black Sold Out
John Hussman 1,040,000 sh (-13.62%)
Louis Moore Bacon 75,000 sh (-25%)
Steven Cohen 2,243,863 sh (-51.48%)
» More
Q1 2013

ENDP Guru Trades in Q1 2013

Mario Gabelli 56,550 sh (New)
Richard Snow 51,040 sh (New)
Louis Moore Bacon 135,000 sh (+80%)
Jeremy Grantham 45,430 sh (+22.78%)
Steven Cohen 2,673,898 sh (+19.16%)
Jim Simons Sold Out
Chuck Royce Sold Out
John Hussman Sold Out
David Dreman Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt 313,273 sh (-12.52%)
» More
» Details

Insider Trades

Latest Guru Trades with ENDP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Sold Out 0.72%$25.06 - $31.66 $ 38.5632%0
David Dreman 2013-03-31 Sold Out 0.07%$25.06 - $31.66 $ 38.5632%0
Mario Gabelli 2013-03-31 New Buy0.01%$25.06 - $31.66 $ 38.5632%56550
Lee Ainslie 2012-12-31 Sold Out 2.1%$25.6 - $32.43 $ 38.5636%0
Scott Black 2012-12-31 Sold Out 1.2%$25.6 - $32.43 $ 38.5636%0
Joel Greenblatt 2012-12-31 Add 48.97%0.18%$25.6 - $32.43 $ 38.5636%358103
Ray Dalio 2012-12-31 Sold Out 0.01%$25.6 - $32.43 $ 38.5636%0
Lee Ainslie 2012-09-30 Reduce -20.96%0.61%$29.2 - $33.68 $ 38.5623%5088143
Joel Greenblatt 2012-09-30 Add 822.71%0.45%$29.2 - $33.68 $ 38.5623%240394
John Hussman 2012-09-30 Reduce -37.1%0.41%$29.2 - $33.68 $ 38.5623%1204000
Ray Dalio 2012-09-30 New Buy0.01%$29.2 - $33.68 $ 38.5623%30243
Lee Ainslie 2012-06-30 Add 16.86%0.42%$29.03 - $38.77 $ 38.5615%6437482
Scott Black 2012-06-30 Add 15.73%0.16%$29.03 - $38.77 $ 38.5615%249122
Joel Greenblatt 2012-06-30 Add 53.03%0.02%$29.03 - $38.77 $ 38.5615%26053
Premium More recent guru trades are included for Premium Members only!!
ยป Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/B 3.90
ENDP's P/B is ranked higher than
50% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. ENDP: 3.90 )
ENDP' s 10-Year P/B Range
Min: 1.48   Max: 6.13
Current: 3.9
1.48
6.13
P/S 1.45
ENDP's P/S is ranked higher than
80% of the 654 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. ENDP: 1.45 )
ENDP' s 10-Year P/S Range
Min: 0.97   Max: 6.1
Current: 1.45
0.97
6.1
PFCF 7.80
ENDP's PFCF is ranked higher than
95% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.96 vs. ENDP: 7.80 )
ENDP' s 10-Year PFCF Range
Min: 4.43   Max: 38.45
Current: 7.8
4.43
38.45
EV-to-EBIT 24.4
ENDP's EV-to-EBIT is ranked lower than
57% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.43 vs. ENDP: 24.4 )
ENDP' s 10-Year EV-to-EBIT Range
Min: 3.9   Max: 71
Current: 24.4
3.9
71
PEG 15.3
ENDP's PEG is ranked lower than
57% of the 263 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.22 vs. ENDP: 15.3 )
ENDP' s 10-Year PEG Range
Min: 0.34   Max: 22.51
Current: 15.3
0.34
22.51
Shiller P/E 65.3
ENDP's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: vs. ENDP: 65.3 )
ENDP' s 10-Year Shiller P/E Range
Min: 10.89   Max: 107.5
Current: 65.3
10.89
107.5

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 6.3
ENDP's Price/Net Current Asset Value is ranked higher than
84% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.20 vs. ENDP: 6.3 )
ENDP' s 10-Year Price/Net Current Asset Value Range
Min: 4.5   Max: 25.1
Current: 6.3
4.5
25.1
Price/DCF (Projected) 0.6
ENDP's Price/DCF (Projected) is ranked higher than
96% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ENDP: 0.6 )
ENDP' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 1
Current: 0.6
0.4
1
Price/Median PS Value 0.5
ENDP's Price/Median PS Value is ranked higher than
96% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. ENDP: 0.5 )
ENDP' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 1.7
Current: 0.5
0.3
1.7
Earnings Yield (Greenblatt) 4.10
ENDP's Earnings Yield (Greenblatt) is ranked higher than
70% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. ENDP: 4.10 )
ENDP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 25.4
Current: 4.1
1.4
25.4
Forward Rate of Return (Yacktman) 7.06
ENDP's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ENDP: 7.06 )
ENDP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 25.7   Max: 56.8
Current: 7.06
25.7
56.8

Business Description

Endo Health Solutions Inc, formerly Endo Pharmaceutical Holdings, was incorporated in the state of Delaware on November 18, 1997. The company operates as a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain. The Company has a majority position in Indevus Pharmaceuticals, a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. Indevus's products include Sanctura and Sanctura XR for overactive bladder, Vantas for advanced prostate cancer, Supprelin LA for central precocious puberty, Delatestryl for the treatment of hypogonadism and Valstar for bladder cancer. The Company, along with Indevus, is developing products for the endocrinology, oncology and urology fields. It has a portfolio of products that includes brand names such as Lidoderm, Opana ER and Opana, Percocet, Frova, and Voltaren Gel. The Company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, anesthesiology, oncology and primary care. It sells products directly to a limited number of pharmacy chains and through a limited number of wholesale drug distributors who, in turn, supply products to pharmacies, hospitals, governmental agencies and physicians. The Company's main competitors include Abbott Laboratories, Johnson & Johnson, Pfizer, Inc., Purdue Pharma, L.P., Allergan, Inc. and Watson Pharmaceuticals Inc. The Company is subject to various federal and state laws and regulations.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:EPV.Germany
ยป More Articles for ENDP

Headlines

Articles On GuruFocus.com
H/C -- winner. Down Mar 02 2013 
greenblatt - low Jan 22 2013 
comment on ENDP Nov 28 2012 
comment on ENDP Jul 09 2012 
Weekly Top Insider Buys: MDT, KMI, WIN, ENDP, OC Jun 25 2012 
Weekly CEO Buys Highlight: UTHR, TAT, PMC, BRCD, ENDP Jun 16 2012 
Endo Pharmaceuticals Holdings Inc. (ENDP) EVP, CFO Alan G Levin sells 16,627 Shares Dec 09 2010 
Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-Q) Nov 02 2010 
Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-Q) Aug 02 2010 
Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-Q) May 04 2010 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK